Evidence map›Paper›PMID 40765306›Full record

ReviewBiomolecules & therapeutics2025

Arrestins as Possible Drug Targets.

Zeynep Nur Cinviz, Elisabetta Moroni, Ozge Sensoy, Giulia Morra, Vsevolod V Gurevich

Abstract readReview
In one paragraph

Review in Biomolecules & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zeynep Nur CinvizGraduate School of Engineering and Natural Sciences, Istanbul Medipol University, Istanbul 34810, Turkey.
Elisabetta MoroniInstitute of Chemical Sciences and Technologies (SCITEC)- National Research Council (CNR), Via Mario Bianco 9, 20131 Milano, Italy.
Ozge SensoyGraduate School of Engineering and Natural Sciences, Istanbul Medipol University, Istanbul 34810, Turkey.
Giulia MorraInstitute of Chemical Sciences and Technologies (SCITEC)- National Research Council (CNR), Via Mario Bianco 9, 20131 Milano, Italy.
Vsevolod V GurevichDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Out of at least 20,000 human proteins fewer than 700 are targeted by drugs. Arrestins regulate G protein-coupled receptors, the largest family of signaling proteins in animals, as well as many receptor-independent signaling pathways. Humans express four arrestin subtypes, two of which are ubiquitous and were already shown to serve as versatile hubs of cellular signaling. So far, arrestin proteins are not directly targeted by any drugs. Here we describe potential targets on arrestins and/or interacting proteins, possible approaches for the development of targeting compounds, expected biological outcomes, and possible research and therapeutic value of targeting the interactions of arrestins with receptors and other signaling and trafficking proteins.

Indexed as

ArrestinCell signalingDrug targetGPCR

Identifiers

PMID40765306
PMCPMC12408197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.